Since Xencor’s founding in 1997, investors have been drawn to our remarkable scientific capabilities around engineering monoclonal antibodies and solid intellectual property which serve as the engine behind our drug development programs. We engineer monoclonal antibodies, and now cytokines, for the potential treatment of patients with cancer and autoimmune diseases. Currently, 20 candidates engineered with our XmAb® technology are in clinical development internally and with partners, which include Novartis, Genentech, Amgen, Alexion, MorphoSys and Gilead, among others. Our XmAb engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. The most recent expansion of our technology is the XmAb bispecific Fc domain, which enables the rapid design and simplified development of antibodies that bind two or more different targets simultaneously and other protein structures, as well. We have used bispecific Fc domains to generate a broad array of novel drug candidates, including: bispecific antibodies that contain an anti-tumor associated antigen binding domain and a second binding domain targeted to CD3, an activating receptor on T cells; bispecific antibodies that promote tumor-selective T-cell activation by targeting multiple checkpoint or co-stimulatory receptors; and cytokines that are potency tuned to improve therapeutic index. The plug-and-play nature of XmAb technologies enables the creation of drug candidates for internal development and the selective licensing and access to one or more XmAb technologies to biopharmaceutical companies to use in developing their own proprietary antibodies with improved properties.